Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 338

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Polycythaemia vera

Not yet recruiting

Phase 2/3 study of bomedemstat versus drug combination to evaluate safety and efficacy in polycythemia vera patients not responding to or intolerant of hydroxyurea

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Adenocarcinoma gastric+1

Not yet recruiting

Durvalumab with chemotherapy drug combination versus surveillance in patients with low‑risk localized stomach or gastroesophageal junction cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Niemann-Pick disease+1

Not yet recruiting

Long‑term safety and tolerability of oral nizubaglustat in patients with rare lysosomal disorders who have completed a prior study

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nizubaglustat

Immune system disorder

Not yet recruiting

Long-Term Safety Study of JNJ-77242113 in Children with Immune System Disorders

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Icotrokinra

Optimizing Meropenem Treatment with Continuous vs Intermittent Infusion in Patients with Foreign-Body Bone and Joint Infections

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Meropenem

Safety Study of DIAG723 and Sodium Chloride in Adults with Hereditary Hemorrhagic Telangiectasia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DIAG723

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Hypoparathyroidism

Not yet recruiting

Study of Encaleret Hemisulfate Hemihydrate for Efficacy, Safety and Tolerability in Adults with Chronic Hypoparathyroidism

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.